This study tests how well a drug called Dato-DXd works for lung cancer patients. Some patients also take another drug called osimertinib. The study compares these to regular chemotherapy, which uses strong medicines to stop cancer cells. The focus is on patients with a specific type of lung cancer called non-small cell lung cancer (NSCLC) and a gene change known as EGFR mutation. The goal is to see how long patients live without the cancer getting worse, known as progression-free survival (PFS).
- Length: Participants are followed until their cancer progresses or side effects are too severe.
- Visits: An end of treatment visit happens within 35 days after the last dose, with a follow-up for safety after about a month.
- Risks: Some patients may experience serious side effects, and only those meeting specific health criteria can join.
To join, patients must have a confirmed diagnosis of NSCLC with EGFR mutation and have tried osimertinib before. They should not have other major health issues. This study helps to find better treatments for lung cancer.
How understandable was the trial content above?
Hard to understand
Easy to understand